Inisiasi Fixed Ratio Combination (FRC) Insulin Glargine/Lixisenatide untuk Orang Dewasa dengan Diabetes Melitus Tipe 2
DOI:
https://doi.org/10.55175/cdk.v50i12.1014Kata Kunci:
Diabetes melitus tipe 2, fixed ratio combination, hiperglikemia, iGlarLixiAbstrak
Hiperglikemia adalah suatu kondisi medis peningkatan kadar glukosa darah yang menjadi karakteristik beberapa penyakit, terutama diabetes melitus. Diabetes melitus (DM) saat ini menjadi salah satu ancaman kesehatan global. Fixed ratio combination insulin glargine dan lixisenatide (iGlarLixi) adalah produk yang mengandung insulin glargine (suatu insulin kerja panjang) dan lixisenatide (agonis reseptor glucagon like peptide-1)
dalam satu injeksi tunggal. Fixed ratio combination menawarkan banyak manfaat klinis bagi orang dewasa dengan diabetes melitus tipe 2.
Unduhan
Referensi
PERKENI. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2021. PB PERKENI; 2021
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017 Estimates of Diabetes and Its Burden in the United States Background [Internet]. 2020. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999-2018. N Engl J Med. 2021;384(23):2219–28.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753–86.
Peng XV, Ayyagari R, Lubwama R, Shi L, Price-Haywood EG, Hollander P, et al. Impact of simultaneous versus sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists on HbA1c in type 2 diabetes: A retrospective observational study. Diabetes Ther. 2020;11(4):995–1005.
American Diabetes Association. Standards of medical care in diabetes—2020 abridged for primary care providers. Clin Diabetes 2020;38(1):10–38.
American Association of Clinical Endocrinology. 2023 AACE consensus statement: Comprehensive type 2 diabetes management algorithm [Internet]. [cited 2023 May 22]. Available from: https://pro.aace.com/clinical-guidance/2023-aace-consensus-statement-comprehensive-type-2-diabetes-management-algorithm?gclid=CjwKCAjwpayjBhAnEiwA-7ena6YcTglvwnpfkBrndI-4EwfS75R2MJUdWOVMCoqTN4U669mhQjePwRoCZ00QAvD_BwE
Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing fixed-ratio combination therapy in type 2 diabetes. Advances in Therapy. 2019;36(2):265–77.
Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes, Obesity and Metabolism. 2014;17(2):145–51.
Kramer W. Exp Clin Endocrinol Diabetes. 1999;107(suppl 2):S52. http://dx.doi.org/10.1055/s-0029-1212151
Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technol Therapeut. 2011 Jun;13(S1):33-42.
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28.
Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides 2010 Sep 24;164(2-3):58–64.
Annex I summary of product characteristics [Internet]. [cited 2023 May 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/suliqua-epar-product-information_en.pdf
Haluzik M, Flekač M, Lengyel C, Zoltán Taybani, Cristian Guja, Mihai BM, et al. Expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide: A Central/Eastern European Perspective. Diabetes Ther. 2020 Apr;11(4):1029-43.
Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of lixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The lixiLan-O randomized trial. Diabetes Care
;39(11):2026–35.
PERKENI. Pedoman pemantauan glukosa darah mandiri 2021. PB PERKENI, editor. PB PERKENI; 2021. 22-10-21-Website-Pedoman-Pemantauan-Glukosa-Darah-Mandiri-Ebook.pdf (pbperkeni.or.id)
Sanofi-Aventis Deutschland GmbH. Lantus® (insulin glargine 100 units/mL) Summary of Product Characteristics, 2017. https://pdf.hres.ca › dpd_pm
Highlights of Prescribing Information Soliqua. BPOM, 2021
Leaflet Informasi untuk Pengguna Soliqua, BPOM 2019
PERKENI. Pedoman petunjuk praktis terapi insulin pada pasien diabetes melitus 2021. PB PERKENI [Internet]. 2021. Available from: https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-_-Website-Pedoman-Petunjuk-Praktis-Terapi-Insulin-Pada-Pasien-Diabetes-Melitus-Ebook.pdf
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Muhammad Ikhsan Mokoagow
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
